E.g., 06/21/2019
E.g., 06/21/2019
Titlesort descending Category Credit Event date Price
AUA2019 Chicago - Virtual Course Pass (2019) $399.00 The AUA2019 Course Pass Bundle included the Live Course Pass PLUS online access to all 80+ Instructional Courses presented at AUA2019. NOTE: This product is only available to AUAU2019 attendees. If you were not able to attend AUA2019 and would like access to this important educational content, please see the AUA2019 Virtual Meeting.  
AUA2019 Chicago - Virtual Meeting (2019) $699.00 Didn't make it to Chicago for the 2019 AUA Annual Meeting? Access the latest science from AUA2019 with the AUA2019 Virtual Meeting! SAVE BIG THROUGH MAY 31: Special Discount on the AUA2019 Virtual Meeting
Basic Urologic Ultrasound (2019)
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
$125.00 The use of ultrasound is fundamental to the practice of urology. Urologists use ultrasound daily in the office and in the surgical setting to diagnose urologic disease and to guide treatment. In order for urologists to achieve the best possible outcomes from this technology they must have a thorough understanding of the physical principles of ultrasound, the principles of image generation and the common artifacts associated with ultrasound. By viewing this online video, urologists will become acquainted with the effects of technique and machine adjustments on image quality.
Best of AUA- BPH: Minimally Invasive/ Surgical Options for Treating mLUTS and BPH (2017) $0.00 This 90 minute FREE non-cme webinar focuses on the topic of BPH.  AUA’s Secretary, Dr. Manoj Monga, is joined by expert faculties Drs. Alexis E. Te, M.D. and Dicken Shiu-Chung Ko for an exciting program featuring didactic lectures on Minimally Invasive/Surgical Options for treating mLUTS and BPH, Medical Therapy with both Mono and Combination Therapy with agents such as alpha blockers, antimuscarinics, 5-alpha reductase inhibitors, PDE-5 inhibitors, as well as step-by-step reviews of surgical videos including:
Best of AUA: OAB: International Webinar (2017) $0.00 AUA is pleased to bring this 90 minute FREE non-cme webinar educational series to the global urologic community.  Dr. Robert J. Evans (Wake Forest) will be joined by expert faculties Drs. Howard B. Goldman (Cleveland Clinic) and Anurag Das (Beth Israel) for an exciting program featuring didactic lectures on the Urodynamic Evaluation and Advances in the Management of Adult Neurogenic Lower Urinary Tract Dysfunction as well as Highlights and Take Home Messages from AUA 2016 for treating Female Urology, Incontinence, and Urodynamics. 
Breaking Down the Barriers: Incorporating New IO Therapies Podcast Series - Biomarkers (2018)
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Non-Physician Participation
$0.00 To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of adverse events, the AUA is producing a series of online activities for clinicians and other healthcare professionals.The 2018 series is comprised of a variety of activities, including four live webinars, webcasts and podcasts plus three podcast addressing the barriers to immunotherapy treatment of GU cancer. All activities are complimentary.
Breaking Down the Barriers: Incorporating New IO Therapies Podcast Series - How to Properly Administer IO Therapies in an Infusion Suite (2018)
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Non-Physician Participation
$0.00 To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of adverse events, the AUA is producing a series of online activities for clinicians and other healthcare professionals.The 2018 series is comprised of a variety of activities, including four live webinars, webcasts and podcasts plus three podcast addressing the barriers to immunotherapy treatment of GU cancer. All activities are complimentary.
Breaking Down the Barriers: Incorporating New IO Therapies Podcast Series - Managing Patient Side Effects (2018)
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Non-Physician Participation
$0.00 To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of adverse events, the AUA is producing a series of online activities for clinicians and other healthcare professionals.The 2018 series is comprised of a variety of activities, including four live webinars, webcasts and podcasts plus three podcast addressing the barriers to immunotherapy treatment of GU cancer. All activities are complimentary.
Castration-Resistant Prostate Cancer (CRPC) Guideline Amendment Webcast (2018)
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC), the AUA and Urology Care Foundation has produced a series of online activities and educational resources for healthcare professionals, patients and caregivers. One of those such activities is this complimentary AUA Castration-Resistant Prostate Cancer Guideline Amendment webcast.
Castration-Resistant Prostate Cancer (CRPC) Guidelines Webcast 074IC (2018)
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
$0.00 This course will review the 2015 update to the 2013 AUA guidelines on castration-resistant prostate cancer. Faculty will explore the rigorous process used in the development of these evidence-based guidelines, as well as discuss new developments and future research needs for this topic. The course will showcase clinical scenarios in urological practice and the correct application of the new AUA guidelines in those instances.
Chemotherapy & Immunotherapy Options for Genitourinary Malignancies: A Primer for the Advanced Practice Provider Webcast 005IC (2018)
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
$0.00 Review of current chemotherapy and immunotherapy regimens for genitourinary malignancies, including bladder, renal, and prostate cancers. Indications, outcomes, and toxicities will be discussed as well as clinical trial concepts. Survivorship issues will also be a focus of the session, which will include short, direct didactic lectures as well as a panel discussion with an interactive component. Standard of care chemotherapy regimens (eg MVAC for urothelial carcinoma) as well as newer immunotherapy options (eg checkpoint inhibition for renal cell carcinoma) will be included.
Chemotherapy and Immunotherapy Options for Genitourinary Malignancies: A Primer for Urologists and Advanced Practice Providers Webcast 023IC (2019)
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
$0.00 Review of current chemotherapy and immunotherapy regimens for genitourinary malignancies, including bladder, renal, prostate, and testis cancers. Indications, outcomes, and toxicities will be discussed as well as clinical trial concepts. Survivorship issues will also be a focus of the session, which will include short, direct didactic lectures as well as a question and answer period. Standard of care chemotherapy regimens (eg MVAC for urothelial carcinoma) as well as newer immunotherapy options (eg checkpoint inhibition for renal cell carcinoma) will be included.
Complex Patient Cases in Bladder Cancer Webcast (2017)
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
$0.00 The AUA developed the Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer initiative to include multiple educational interventions to improve the urologist, medical oncologist, and other healthcare provider's ability to care for patients with bladder cancer. These activities are designed to increase the clinician's competence in the application of new and emerging treatment options, including the sequencing and associated side effects of those options.
Contemporary Pharmacotherapy for OAB 2019: Monotherapy and Combined Pharmacotherapy to Optimize Treatment Webcast 035IC (2019)
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
$0.00 Much has been written and debated about drug treatment of overactive bladder (OAB) over the past two decades. Nevertheless, the field continues to evolve. OAB pharmacotherapy remains an area of active investigation and innovation. Patient communication, including goal setting with respect to realistic expectations of therapy, and therapeutic algorithms are important factors in improving patient outcomes.
Contemporary Pharmacotherapy for OAB Webcast 031IC (2018)
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
$0.00 Much has been written and debated about drug treatment of overactive bladder (OAB) over the past two decades. Nevertheless, the field continues to evolve. OAB pharmacotherapy remains an area of active investigation and innovation. Patient communication, including goal setting with respect to realistic expectations of therapy, and therapeutic algorithms are important factors in improving patient outcomes.

Pages